U.S., Feb. 19 -- ClinicalTrials.gov registry received information related to the study (NCT06833268) titled 'Real-world Outcomes of Patients With HER2+ Metastatic Breast Cancer After Treatment With Trastuzumab Deruxtecan' on Feb. 12.
Brief Summary: This study will explore treatment patterns and clinical outcomes using the US-based Flatiron Health database to describe patients with HER2+ mBC who were previously treated with T-DXd to better characterize this population and inform internal decision making in this rapidly changing therapeutic landscape.
Study Start Date: Jan. 20
Study Type: OBSERVATIONAL
Condition:
HER2-positive Breast Cancer
Intervention:
OTHER: No drug
This is an non-interventional, observational study. No drug will b...